Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses.

ABSTRACT:

Background

High-dose short-term methylprednisolone is the recommended treatment in the management of multiple sclerosis relapses, although it has been suggested that lower doses may be equally effective. Also, glucocorticoids are associated with multiple and often dose-dependent adverse effects. This quantitative benefit-risk assessment compares high- and low-dose methylprednisolone (at least 2000 mg and less than 1000 mg, respectively, during at most 31 days) and a no treatment alternative, with the aim of determining which regimen, if any, is preferable in multiple sclerosis relapses.

Methods

An overall framework of probabilistic decision analysis was applied, combining data from different sources. Effectiveness as well as risk of non-serious adverse effects were estimated

SUBMITTER: Caster O 

PROVIDER: S-EPMC4609048 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature